Item 1.01. Entry into a Material Definitive Agreement.

The information set forth below in Item 2.03 is incorporated by reference into this Item 1.01.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an


           Off-Balance Sheet Arrangement of a Registrant.

On April 7, 2020, Tenet Healthcare Corporation ("Tenet") issued $700,000,000 in aggregate principal amount of 7.500% senior secured first lien notes due 2025 (the "Notes").

The Notes were issued pursuant to an indenture, dated November 6, 2001 (the "Base Indenture"), between Tenet and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York as trustee (in such capacity, the "Trustee"), as supplemented by the thirty-fourth supplemental indenture (the "Thirty-Fourth Supplemental Indenture" and, together with the Base Indenture, the "Indenture"), among Tenet, the guarantors party thereto, and the Trustee, dated April 7, 2020.

Tenet intends to use the net proceeds of the sale of the Notes, after payment of fees and expenses, to repay a portion of the $500 million aggregate principal amount of borrowings outstanding under its senior secured revolving credit facility or for general corporate purposes.

The Indenture contains covenants that, among other things, restrict Tenet's ability and the ability of its subsidiaries to: incur liens; provide subsidiary guarantees; consummate asset sales; enter into sale and lease-back transactions; or consolidate, merge or sell all or substantially all of their assets, other than in certain transactions between one or more of Tenet's wholly owned subsidiaries and Tenet. These restrictions, however, are subject to a number of important exceptions and qualifications. In particular, there are no restrictions on Tenet's ability or the ability of its subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities).

The Indenture also provides that the Notes may become subject to redemption under certain circumstances, including a change of control (as defined in the Indenture) of Tenet. Prior to April 1, 2022, Tenet may, at its option, redeem the Notes in whole or in part, at a redemption price equal to 100% of the principal amount of the Notes being redeemed plus the make-whole premium set forth in the Indenture, together with accrued and unpaid interest. On and after April 1, 2022, Tenet may, at its option, redeem the Notes in whole or in part, at certain redemption prices (expressed as percentages of the principal amount thereof) set forth in the Indenture, together with accrued and unpaid interest.

In connection with the issuance of the Notes, Tenet also entered into an exchange and registration rights agreement, dated as of April 7, 2020 (the "Registration Rights Agreement"), with Barclays Capital Inc. ("Barclays") as representative of the other initial purchasers of the Notes named therein. Pursuant to the Registration Rights Agreement, in certain circumstances, Tenet has agreed to use commercially reasonable efforts to register the Notes with the Securities and Exchange Commission if the Notes have not become freely tradable (as defined in the Registration Rights Agreement) on or before the 380th day following the date hereof.

The foregoing is a summary and is qualified by reference to the Base Indenture, the Thirty-Fourth Supplemental Indenture and the Registration Rights Agreement, which are filed herewith as Exhibits 4.1, 4.2 and 10.1, respectively, and are incorporated herein by reference.

--------------------------------------------------------------------------------

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibits are filed as a part of this Report.



 Exhibit
   No.                                        Description

    4.1             Indenture dated as of November 6, 2001, between Tenet and the
                  Bank of New York Mellon Trust Company, N.A., as successor trustee
                  to The Bank of New York (incorporated by reference to Tenet's
                  Current Report on Form 8-K, dated November 6, 2001 and filed
                  November 9, 2001).

    4.2             Thirty-Fourth Supplemental Indenture dated as of April 7, 2020,
                  among Tenet, the guarantors party thereto and The Bank of New York
                  Mellon Trust Company, N.A.

   10.1             Exchange and Registration Rights Agreement dated as of April 7,
                  2020, among Tenet, the guarantors party thereto and Barclays
                  Capital Inc. as representative of the other initial purchasers of
                  the Notes named therein.

   104            Cover page from Tenet Healthcare Corporation's Current Report on
                  Form 8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses